Neurologic complications after allogeneic hematopoietic stem cell transplantation: risk factors and impact

被引:37
|
作者
Dowling, M. R. [1 ,2 ,3 ,4 ]
Li, S. [5 ]
Dey, B. R. [6 ]
McAfee, S. L. [6 ]
Hock, H. R. [6 ]
Spitzer, T. R. [6 ]
Chen, Y-B [6 ]
Ballen, K. K. [7 ]
机构
[1] Walter & Eliza Hall Inst Med Res, Immunol Div, Parkville, Vic, Australia
[2] Univ Melbourne, Dept Med Biol, Parkville, Vic, Australia
[3] Royal Brisbane & Womens Hosp, Herston, Qld, Australia
[4] Univ Queensland, Sch Med, Brisbane, Qld, Australia
[5] Dana Farber Canc Inst, Boston, MA 02115 USA
[6] Massachusetts Gen Hosp, Canc Ctr, Boston, MA 02114 USA
[7] Univ Virginia, Canc Ctr, Univ Virginia Hlth Syst, Dept Med,Stem Cell Transplant Program, 1215 Lee St, Charlottesville, VA 22903 USA
基金
英国医学研究理事会;
关键词
BONE-MARROW-TRANSPLANTATION; REVERSIBLE ENCEPHALOPATHY SYNDROME; CORD BLOOD TRANSPLANTATION; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; NERVOUS-SYSTEM COMPLICATIONS; HIGH-DOSE CHEMOTHERAPY; LIMBIC ENCEPHALITIS; COMPETING RISK; CYCLOSPORINE-A; TACROLIMUS;
D O I
10.1038/bmt.2017.239
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
Neurologic complications (NCs) may be a significant source of morbidity and mortality after hematopoietic cell transplantation (HCT). We performed a retrospective study of 263 consecutive patients undergoing allogeneic HCT for hematological malignancies to determine the incidence, risk factors and clinical impact of NCs in the first 5 years after HCT. We determined the incidence of central nervous system (CNS) infection, intracranial hemorrhage, ischemic stroke, metabolic encephalopathy, posterior reversal encephalopathy syndrome, seizure and peripheral neuropathy. In all, 50 patients experienced 63 NCs-37 early (<= day + 100), 21 late (day + 101 to 2 years) and 5 very late (2 to 5 years). The 1- and 5-year cumulative incidences of all NCs were 15.6% and 19.2%, respectively, and of CNS complication (CNSC; all of the above complications except peripheral neuropathy) were 12.2 and 14.5%. Risk factors for CNSC were age (hazard ratio (HR) = 1.06 per year, P = 0.0034), development of acute GvHD grade III-IV (HR = 2.78, P=0.041), transfusion-dependent thrombocytopenia (HR = 3.07, P = 0.025) and delayed platelet engraftment (> 90th centile; HR = 2.77, P = 0.043). CNSCs negatively impacted progression-free survival (HR = 2.29, P = 0.0001), overall survival (HR = 2.63, P < 0.0001) and non-relapse mortality (HR = 8.51, P < 0.0001). NCs after HCT are associated with poor outcomes, and usually occur early after HCT.
引用
收藏
页码:199 / 206
页数:8
相关论文
共 50 条
  • [41] Risk factors for bronchiolitis obliterans in allogeneic hematopoietic stem-cell transplantation for leukemia
    Tomas, LHS
    Loberiza, FR
    Klein, JP
    Layde, PM
    Lipchik, RJ
    Rizzo, JD
    Bredeson, CN
    Horowitz, MM
    CHEST, 2005, 128 (01) : 153 - 161
  • [42] Neuromuscular complications after hematopoietic stem cell transplantation
    Koeppen, Susanne
    Thirugnanasambanthan, Abhiyrahmi
    Koldehoff, Michael
    SUPPORTIVE CARE IN CANCER, 2014, 22 (09) : 2337 - 2341
  • [43] Corneal complications after hematopoietic stem cell transplantation
    Mittelviefhaus, H
    Auw-Hädrich, C
    OPHTHALMOLOGE, 2003, 100 (03): : 222 - 229
  • [44] Late complications after hematopoietic stem cell transplantation
    Tichelli, Andre
    Rovo, Alicia
    Passweg, Jakob
    Schwarze, Carl Philipp
    Van Lint, Maria Teresa
    Arat, Mutlu
    Socie, Gerard
    EXPERT REVIEW OF HEMATOLOGY, 2009, 2 (05) : 583 - 601
  • [45] Outcomes of Lung Transplantation after Allogeneic Hematopoietic Stem Cell Transplantation
    Cheng, Guang-Shing
    Edelman, Jeffrey D.
    Madtes, David K.
    Martin, Paul J.
    Flowers, Mary E. D.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2014, 20 (08) : 1169 - 1175
  • [47] Risk factors for late infections after allogeneic hematopoietic stem cell transplantation from a matched related donor
    Robin, Marie
    Porcher, Raphaeel
    Araujo, Renato De Castro
    De Latour, Regis Peffault
    Devergie, Agnes
    Rocha, Vanderson
    Largbero, Jerome
    Ades, Lionel
    Ribaud, Patricia
    Mary, Jean-Yves
    Socie, Gerard
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2007, 13 (11) : 1304 - 1312
  • [48] Risk Factors for Progression from Cytomegalovirus Viremia to Cytomegalovirus Disease after Allogeneic Hematopoietic Stem Cell Transplantation
    Jang, Ji Eun
    Hyun, Shin Young
    Kim, Yun Deok
    Yoon, Sul Hee
    Hwang, Doh Yu
    Kim, Soo Jeong
    Kim, Yuri
    Kim, Jin Seok
    Cheong, June-Won
    Min, Yoo Hong
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2012, 18 (06) : 881 - 886
  • [49] Risk factors for fatal cardiac complications after allogeneic hematopoietic cell transplantation: Japanese Society for Transplantation and Cellular Therapy transplant complications working group
    Yanagisawa, Ryu
    Tamaki, Masaharu
    Tanoshima, Reo
    Misaki, Yukiko
    Uchida, Naoyuki
    Koi, Satoshi
    Tanaka, Takashi
    Ozawa, Yukiyasu
    Matsuo, Yayoi
    Tanaka, Masatsugu
    Ikegame, Kazuhiro
    Katayama, Yuta
    Matsuoka, Ken-Ichi
    Ara, Takahide
    Kanda, Yoshinobu
    Matsumoto, Kimikazu
    Fukuda, Takahiro
    Atsuta, Yoshiko
    Kato, Motohiro
    Nakasone, Hideki
    HEMATOLOGICAL ONCOLOGY, 2023, 41 (03) : 535 - 545
  • [50] Immune-Mediated Complications after Hematopoietic Stem Cell Transplantation
    Li, Zhuoyan
    Rubinstein, Samuel M.
    Thota, Ramya
    Savani, Malvi
    Brissot, Eolia
    Shaw, Bronwen E.
    Majhail, Navneet S.
    Mohty, Mohamad
    Savani, Bipin N.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (08) : 1368 - 1375